(Q45999339)

18 December 2017

title

The caveolin-1 binding domain of HIV-1 glycoprotein gp41 (CBD1) contains several overlapping neutralizing epitopes. (English)

1 reference

18 December 2017

author name string

Rima Benferhat

1

1 reference

18 December 2017

Bernard Krust

2

1 reference

18 December 2017

Marie-Anne Rey-Cuillé

3

1 reference

18 December 2017

Ara G Hovanessian

4

1 reference

18 December 2017

language of work or name

English

0 references

publication date

10 April 2009

1 reference

18 December 2017

published in

Vaccine

1 reference

18 December 2017

volume

27

1 reference

18 December 2017

issue

27

1 reference

18 December 2017

page(s)

3620-3630

1 reference

18 December 2017

cites work

HIV vaccines 1983-2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

HIV-1 neutralization: mechanisms and relevance to vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Caveolae: anchored, multifunctional platforms in the lipid ocean

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Multiple functions of caveolin-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Anchorage of HIV on permissive cells leads to coaggregation of viral particles with surface nucleolin at membrane raft microdomains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Plasma membrane rafts play a critical role in HIV-1 assembly and release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Human immunodeficiency virus type 1 virological synapse formation in T cells requires lipid raft integrity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

The immunogenic CBD1 peptide corresponding to the caveolin-1 binding domain in HIV-1 envelope gp41 has the capacity to penetrate the cell membrane and bind caveolin-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

A closer look at proteolysis and MHC-class-II-restricted antigen presentation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Methods of enhancing the frequency of antigen-specific hybridomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

The HB-19 pseudopeptide 5[Kpsi(CH2N)PR]-TASP inhibits attachment of T lymophocyte- and macrophage-tropic HIV to permissive cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

RGD motif enhances immunogenicity and adjuvanicity of peptide antigens following intranasal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

An ingenious design for peptide vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Cell biology of antigen processing in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Major histocompatibility class II molecules prevent destructive processing of exogenous peptides at the cell surface of macrophages for presentation to CD4 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Characterization of a novel human anti-HIV-1 gp41 IgM monoclonal antibody designated clone 37.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

ELISA analysis of beta-secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

The antiviral activity of antibodies in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.057

10.1016/J.VACCINE.2009.03.057

7 January 2021

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017